Published on 29/11/2025

Statistical Similarity: TOST, Equivalence, and Non-Inferiority

In the realm of biosimilars, analytical comparability is paramount for ensuring product quality, safety, and efficacy. The use of statistical methodologies such as the Two-One-Sided Test (TOST) for equivalence testing, bridging justifications, and process drift monitoring are all essential components in the lifecycle of biosimilar development. This tutorial will guide pharmaceutical professionals through the step-by-step processes necessary to properly implement these principles, ensuring compliance with regulatory expectations set forth by agencies like the FDA, EMA, and MHRA.

Understanding Biosimilar Analytical Comparability

Biosimilars are biologic medical products highly similar to an already approved reference product. The concept of biosimilar analytical comparability revolves around demonstrating that the biosimilar drug can elicit similar clinical effects as its reference counterpart. This involves extensive validation of quality attributes which are known as Critical Quality Attributes (CQA).

To demonstrate comparability, regulatory authorities expect the following steps to be adhered to:

• Conduct a thorough CQA mapping to identify the key attributes influencing product quality.
• Implement fingerprint analytics to characterize and compare the biosimilar to the reference product.
• Develop a robust process drift monitoring program to identify any variations in manufacturing processes.

Together, these methods establish a sound basis for equivalence testing, supporting a rigorous framework for regulatory submission and approval.

Step 1: Critical Quality Attribute (CQA) Mapping

Critical Quality Attributes (CQAs) are the physical, chemical, biological, or microbiological properties or characteristics that need to be controlled in order to ensure the desired product quality. In the context of biosimilars, identifying these CQAs is the first essential step in demonstrating comparability.

To perform CQA mapping, follow these steps:

1. Identify Potential CQAs: Begin by reviewing the reference product’s specifications, quality data, and any regulatory guidance documents related to the product class. For biosimilars, refer specifically to Q5E Comparability and Q6B specifications.
2. Prioritize CQAs: Based on their impact on safety and efficacy, prioritize the CQAs through risk assessment methodologies, such as Failure Mode Effect Analysis (FMEA).
3. Develop Analytical Methods: Establish analytical methods that are capable of quantifying the CQAs effectively. These methods must be validated following ICH guidelines to ensure consistency across results.

Proper CQA mapping paves the way for next steps in analytical comparability and equivalence testing.

Step 2: Implementing Fingerprint Analytics

Fingerprint analytics refers to the advanced analytical methods that provide a comprehensive characterization of the biosimilar and the reference biologic. This is crucial for demonstrating that the two products are analogous in their quality attributes.

To deploy fingerprint analytics, the following steps should be taken:

1. Select Analytical Techniques: Utilize techniques such as High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Fourier Transform Infrared Spectroscopy (FTIR) to generate a fingerprint profile of both the biosimilar and the reference product.
2. Establish Comparison Metrics: Define metrics for comparing the fingerprint data, like %Similarity scores or delta values. These quantitative metrics provide clarity on the degree of similarity between the two products.
3. Perform Data Analysis: Utilize statistical software tools to analyze the fingerprint data, supporting the determination of equivalency.

Fingerprints generated through these analytics are critical for evaluating the similarity of the biosimilars to their reference products, making this step essential in the comparability assessment.

Step 3: Equivalence Testing Through TOST

The TOST procedure is a widely accepted method for statistical equivalence testing, facilitating determination of whether a biosimilar is statistically similar to its reference product. To implement TOST for equivalence testing, follow this structured approach:

1. Define Acceptance Criteria: Establish predefined equivalence margins, which should be based on clinically relevant differences and regulatory recommendations. These margins should be grounded in extensive clinical practice and prior data.
2. Conduct the Tests: Use statistical software to carry out the TOST procedure. Essentially, this involves performing two one-sided tests to determine if the biosimilar falls within the acceptance criteria established.
3. Interpret Results: Review the statistical outputs critically. If both tests confirm that the confidence intervals fall within the equivalence margins, the biosimilar can be deemed statistically similar to the reference product.

RD professionals should be proficient in interpreting the results from TOST to evaluate the equivalence claims of the biosimilar.

Step 4: Process Drift Monitoring

Process drift describes variations that occur during manufacturing which can affect the quality of biopharmaceutical products. Monitoring for process drift is crucial in ensuring that the manufacturing process remains within established parameters over time.

To establish a comprehensive process drift monitoring strategy, consider the following steps:

1. Define Process Parameters: Identify critical process parameters (CPPs) that impact the manufacturing of the biosimilar. Particular attention should be given to parameters that directly influence CQAs identified in earlier stages.
2. Implement Continuous Monitoring: Integrate techniques that continuously monitor the defined CPPs. Real-time data should be collected and analyzed to detect any deviations promptly.
3. Perform Periodic Review: Conduct regular retrospective analyses of production data to assess trends over time. This can help in early identification of potential issues related to process drift.

Robust process drift monitoring can prevent significant quality deviations, thereby ensuring ongoing compliance with regulatory standards.

Step 5: Bridging Justifications and Regulatory Submission

Once equivalence has been established through CQAs, fingerprint analytics, and TOST, it is crucial to provide comprehensive bridging justifications in regulatory submissions. These justifications support claims of analytical comparability and are necessary for a successful application.

Prepare your bridging justifications by:

1. Documenting the Methodology: Clearly detail the analytical methods used and justify the chosen acceptance criteria based on scientific literature and clinical practice.
2. Providing Robust Data: Include all relevant data from CQA assessments, fingerprint analytics, and equivalence testing results to support your comparability claims.
3. Engaging with Regulatory Bodies: Seek guidance from regulatory authorities throughout the development process. Utilize their feedback to shape your submission, ensuring compatibility with their expectations.

Clear, concise, and well-structured bridging justifications will enhance the likelihood of regulatory acceptance.

Conclusion

In summary, a detailed approach to biosimilar analytical comparability encompasses multiple sophisticated strategies, including CQA mapping, fingerprint analytics, TOST equivalence testing, process drift monitoring, and bridging justifications. Each step plays a crucial role in ensuring that a biosimilar can be considered equivalent to its reference product in terms of quality, safety, and efficacy.

Pharmaceutical professionals involved in biosimilar development should adhere closely to these guidelines, ensuring compliance with standards from regulatory agencies such as the FDA, EMA, and MHRA. This framework may not only facilitate successful regulatory submissions but also foster confidence in the growing biosimilars market.